Hormonal
Higher baseline total testosterone predicts greater long-term weight loss and waist circumference reduction in both males and females with type 2 diabetes undergoing intensive lifestyle intervention.
If you have type 2 diabetes, your baseline testosterone levels may dictate how effectively your diet and exercise efforts lead to weight loss and waist circumference reduction. Both men and women with higher testosterone tend to see bigger improvements in weight and waist size from lifestyle changes. This suggests that knowing your hormone profile could help tailor your lifestyle prescription for better weight outcomes.
Higher baseline total T predicted greater long-term weight(p=0.013 females; 0.003 males) and WC loss(p=0.061 females; 0.035 males)
Why this rating
Large sample size, long follow-up, and rigorous statistical correction in a randomized controlled trial ancillary study.
Source
Heterogeneity of effect of Intensive lifestyle intervention on cardiometabolic risk factors by sex hormones in diabetes
Chigolum P. Oyeka et al. · medRxiv · 2025
DOI 10.1101/2025.09.02.25334965
More from this paper
- In males with type 2 diabetes, higher baseline endogenous total testosterone and lower estradiol levels significantly enhance the reduction of triglycerides achieved through intensive lifestyle intervention.Good
- In females with type 2 diabetes, higher baseline sex hormone-binding globulin (SHBG) significantly enhances the reduction of LDL cholesterol achieved through intensive lifestyle intervention.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →